Coro Global (CGLO) 10-K 1 Apr 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 31, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'Medefile International, Inc.	'	'
Entity Central Index Key	'0000842013	'	'
Trading Symbol	'mdfi	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-Known Seasoned Issuer	'No	'	'
Entity Common Stock, Shares Outstanding	'	40,706,899	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Public Float	'	'	$15,473,489

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets	'	'
Cash	$266,843	$234,356
Accounts receivable	2,914	391
Inventory	54,507	55,458
Merchant services reserve	14,818	64,319
Prepaid insurance	1,057	998
Total current assets	340,139	355,522
Website development, net of accumulated amortization	261,340	167,245
Furniture and equipment, net of accumulated depreciation	413	1,529
Intangibles	1,339	1,339
Total assets	603,231	525,635
Current Liabilities	'	'
Accounts payable and accrued liabilities	52,915	138,211
Convertible debenture - net of discount of $101,836 and $0, respectively	9,177	'
Deferred revenues	2,075	4,313
Derivative liability	1,062,141	5,618,819
Total Current Liabilities	1,126,308	5,761,343
Stockholders' Deficit	'	'
Preferred stock, $.0001 par value: 10,000,000 authorized, no shares issued and outstanding	'	'
Common stock, $.0001 par value: 500,000,000 authorized; 40,706,899 and 11,413,189 shares issued and outstanding on December 31, 2013 and 2012, respectively	4,070	1,141
Additional paid in capital	27,099,030	23,886,499
Common stock to be issued	69,920	'
Accumulated deficit	-27,696,097	-29,123,348
Total stockholders' deficit	-523,077	-5,235,708
Total liabilities and stockholder's deficit	$603,231	$525,635

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]	'	'
Net of discount, Convertible debenture	$101,836	$0
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	40,706,899	11,413,189
Common stock, shares outstanding	40,706,899	11,413,189

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]	'	'
Revenue	$40,059	$39,217
Cost of goods sold	1,331	4,098
Gross profit	38,728	35,119
Operating expenses	'	'
Selling, general and administrative expenses	962,156	1,189,182
Compensation expense	'	9,792,000
Depreciation and amortization expenses	6,362	29,731
Total operating expenses	968,518	11,010,913
Loss from operations	-929,790	-10,975,794
Other income (expenses)	'	'
Interest expense - convertible note	-1,013	'
Interest expense - discount on convertible note	-8,164	'
Gain (loss) on changes in fair value of derivative liabilities	2,366,218	-429,131
Total other income (expense)	2,357,041	-429,131
Net income (loss) before income tax	1,427,251	-11,404,925
Provision for income tax	'	'
Net income (loss)	$1,427,251	($11,404,925)
Net income (loss) per share: basic and diluted	$0.07	($1.47)
Weighted average share outstanding	21,232,854	7,783,599

Statement_of_Stockholders_Equi

Statement of Stockholders' Equity (Deficit) (USD $)	Total	Preferred	Common Stock	APIC	Common Stock Payable	Accumulated Deficit
Beginning Balance at Dec. 31, 2011	$52,409	'	$79	$17,746,753	$24,000	($17,718,423)
Beginning Balance, Shares at Dec. 31, 2011	'	'	791,653	'	'	'
Common stock issued for consultants	102,859	'	3	102,856	'	'
Common stock issued for consultants (in shares)	'	'	34,714	'	'	'
Common stock issued for stock payable	'	'	1	'	'	'
Common stock issued for stock payable (in shares)	'	'	1,600	23,999	-24,000	'
Shares issued, value	100,000	100,000	'	'	'	'
Preferred Stock Sale (in shares)	'	100,000	'	'	'	'
Conversion of preferred stock to common stock	'	-100,000	20	99,980	'	'
Conversion of preferred stock to common stock (in shares)	'	-100,000	200,000	'	'	'
Common stock sale	1,200,000	'	240	1,199,760	'	'
Common stock sale (in shares)	'	'	2,400,000	'	'	'
Adjustment to derivitave liability	-5,078,051	'	'	-5,078,051	'	'
Common stock issued for anti-dilution	'	'	635	-635	'	'
Common stock issued for anti-dilution (in shares)	'	'	6,348,132	'	'	'
Common stock issued for compensation	9,792,000	'	163	9,791,837	'	'
Common stock issued for compensation (in shares)	'	'	1,632,000	'	'	'
Rounding for stock split	'	'	5,090	'	'	'
Net loss	-11,404,925	'	'	'	'	-11,404,925
Ending Balance at Dec. 31, 2012	-5,235,708	'	1,141	23,886,499	'	-29,123,348
Ending Balance, Shares at Dec. 31, 2012	'	'	11,413,189	'	'	'
Common stock sale	915,000	'	1,742	913,258	'	'
Common stock sale (in shares)	'	'	17,421,429	'	'	'
Adjustment to derivitave liability	2,190,460	'	'	2,190,460	'	'
Common stock issued for anti-dilution	'	'	1,187	-1,187	'	'
Common stock issued for anti-dilution (in shares)	'	'	11,872,281	'	'	'
Convertible debenture discount	110,000	'	'	110,000	'	'
Common stock payable	69,920	'	'	'	69,920	'
Net loss	1,427,251	'	'	'	'	1,427,251
Ending Balance at Dec. 31, 2013	($523,077)	'	$4,070	$27,099,030	$69,920	($27,696,097)
Ending Balance, Shares at Dec. 31, 2013	'	'	40,706,899	'	'	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities	'	'
Net income (loss)	$1,427,251	($11,404,925)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	1,116	8,749
Amortization	5,245	20,982
Interest expense - covertible debenture	1,013	'
Interest expense - BCF on convetible debenture	8,164	'
Stock based compensation	'	9,792,000
Stock based services	'	102,859
(Gain) loss in fair value of derivitave liabilities	-2,366,218	429,131
Changes in operating assets and liabilities	'	'
Accounts receivable	-2,523	226
Inventory	951	-1,533
Prepaid insurance	-59	57
Accounts payable and accrued liabilities	-85,296	-42,032
Merchant services reserve	49,501	-1,789
Deferred revenue	-2,238	-5,542
Net cash used in operating activities	-963,093	-1,101,817
Cash flows from investing activities	'	'
Website development	-99,340	-162,000
Net cash used in investing activities	-99,340	-162,000
Cash flow from financing activities	'	'
Proceeds from convertible debenture - related party	110,000	'
Proceeds from common stock subscription	69,920	'
Proceeds from common stock sale	915,000	1,300,000
Net cash provided by financing activities	1,094,920	1,300,000
Net increase in cash and cash equivalents	32,487	36,183
Cash and cash equivalents at beginning of period	234,356	198,173
Cash and cash equivalents at end of period	266,843	234,356
Supplemental disclosure of cash flow information	'	'
Cash paid for interest	'	'
Cash paid for income taxes	'	'
Common stock issued for consulting service	'	$102,859

BASIS_OF_PRESENTATION_AND_NATU

BASIS OF PRESENTATION AND NATURE OF BUSINESS OPERATIONS	12 Months Ended
	Dec. 31, 2013
Basis of Presentation and Nature of Business Operations [Abstract]	'
BASIS OF PRESENTATION AND NATURE OF BUSINESS OPERATIONS	'
	1. BASIS OF PRESENTATION AND NATURE OF BUSINESS OPERATIONS
	Basis of Presentation
	The accompanying financial statements present on a consolidated basis the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation
	Nature of Business Operations
	Medefile International, Inc. has developed and globally markets a proprietary, patient-centric, Internet-enabled Personal Health Record (iPHR) system for gathering, digitizing, maintaining, accessing and sharing an individual’s actual medical records. Medefile's goal is to revolutionize the medical industry by bringing patient-centric digital technology to the business of medicine. Medefile intends to accomplish its objective by providing individuals with a simple and secure way to access their lifetime of actual medical records in an efficient and cost-effective manner. Medefile's products and services are designed to provide healthcare providers with the ability to reference their patients’ actual past medical records, thereby ensuring the most accurate treatment and services possible while simultaneously reducing redundant procedures.
	Interoperable with most electronic medical record systems utilized by physician practices, clinics, hospitals and other care providers, the highly secure, feature-rich MedeFile iPHR solution has been designed to gather all of its members’ actual medical records on behalf of each member, and create a single, comprehensive Electronic Health Record (EHR). The member can access his/her records 24-hours a day, seven days a week – or authorize a third party user – on any web-enabled device (PC, cell phone, PDA, e-reader, et al), as well as the portable MedeFile flash drive/keychain or branded UBS-bracelet.
	By subscribing to the MedeFile system, members empower themselves to take control of their own health and well-being, and empower their healthcare providers to make sound and lifesaving decisions with the most accurate, up-to-date medical information available.  In addition, with MedeFile, members enjoy the peace of mind that comes from knowing that their medical records are protected from fire, natural disaster, document misplacement or the closing of a medical or dental practice.
	MedeFile believes it enjoys a number of competitive advantages over other firms within the medical records marketplace, including:
	●	MedeFile has developed products and services geared to the patient, while containing the depth and breadth of information required by treating physicians and medical personnel.
	●	MedeFile does all the work of collecting and updating medical information on an ongoing basis; the function of our products’ dependence on the patient taking action is minimal – particularly when compared to patient action required to support competing solutions.
	●	MedeFile provides a complete medical record. Other companies claim complete longitudinal records, but in reality only provide histories (usually completed by the member/patient), which are by no means complete or necessarily accurate records.
	●	MedeFile provides a coherent mix of services and products that are intended to improve the quality of healthcare by enabling the patient to manage and access the information normally retained by doctors and other care providers.
	Going Concern
	The accompanying financial statements have been prepared contemplating a continuation of the Company as a going concern. However, the Company has reported a net income of $1,427,251 for the year ended December 31, 2013.  During the comparable year ended 2012, the Company had a net loss of $11,404,925, as a direct result of the change in valuation of the Company’s warrant derivative. The Company had an accumulated deficit of $27,696,097 as of December 31, 2013.  The Company has negative working capital of $786,169 as of December 31, 2013.
	The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The operating losses raise substantial doubt about the Company's ability to continue as a going concern. The Company's ability to obtain additional financing depends on the availability of its borrowing capacity, the success of its growth strategy and its future performance, each of which is subject to general economic, financial, competitive, legislative, regulatory, and other factors beyond the Company's control.
	We will need additional investments in order to continue operations to cash flow break even. Additional investments are being sought, but we cannot guarantee that we will be able to obtain such investments. Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms.
	However, the trading price of our common stock could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek alternative financing. Further, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we will have to curtail our operations.
	Cash and Cash Equivalents
	For purposes of these financial statements, cash and cash equivalents includes highly liquid debt instruments with maturity of less than three months.
	Concentrations of Credit Risk
	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.  Currently our operating account is not above the FDIC limit.
	Advertising
	The Company follows the policy of charging the costs of advertising to expense as incurred. The Company incurred advertising costs for the year ended December 31, 2013 and 2012 of approximately $0 and $0 respectively.
	Income Taxes
	The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
	The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. A valuation allowance is established against deferred tax assets that do not meet the criteria for recognition. In the event the Company were to determine that it would be able to realize deferred income tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.
	The Company follows the accounting guidance which provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more-likely-than-not recognition threshold at the effective date to be recognized initially and in subsequent periods. Also included is guidance on measurement, recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
	Property and Equipment
	Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives being 3 years up to 10 years.
	Trademark Costs
	Trademark costs incurred in the registration and acquisition of trademarks and trademark rights are capitalized. These costs will be amortized over the legal life of the related trademark once the trademark is awarded. The Company performs an annual review of its identified intangible assets to determine if facts and circumstances exist which indicate that the useful life is shorter than originally estimated or that the carrying amount of the assets may not be recoverable.
	The Company expenses all software costs associated with the conceptual formulation and evaluation of alternatives until the application development stage has been reached. Costs to improve or support the technology are expensed as these costs are incurred.
	Website Development
	The Company's policy is to capitalize website development costs at original cost and amortize the balance over the life of the product.  The life of website is determined at completion of the project. The Company reviews the amounts capitalized for impairment whenever events or circumstances indicate that the carrying amounts of the assets may not be recoverable.
	The Company expenses all development costs associated with the conceptual formulation and evaluation of alternatives until the application development stage has been reached. Costs to improve or support the technology are expensed as these costs are incurred.
	Revenue Recognition
	The Company generates revenue from licensing the right to utilize its proprietary software for the storage and distribution of healthcare information to individuals and affinity groups. For revenue from product sales, the Company recognizes revenue on four basic criteria which must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
	Deferred Revenue
	The Company generally receives subscription fees for its services. From time to time, the Company will receive quarterly or annual subscriptions paid in advance and deferred revenue is recorded at that time. The deferred revenue is amortized into revenue on a pro- rata basis each month. Customers with quarterly or annual subscriptions may cancel their subscriptions and request a refund for future months' revenues at any time. Therefore, a liability is recorded to reflect the amounts that are potentially refundable. At December 31, 2013 and December 31, 2012, deferred revenue totaled $2,075 and$4,313, respectively.
	Reclassifications
	Certain reclassifications have been made in prior periods financial statements to conform to classifications used in the current period.
	Recent Accounting Pronouncements
	There are no recent accounting pronouncements that are expected to have a material effect on the Company’s financial statements.
	Fair Value of Financial Instruments
	Cash and Equivalents, Deposits In-Transit, Receivables, Prepaid and Other Current Assets, Accounts Payable, Accrued Salaries and Wages and Other Current Liabilities
	The carrying amounts of these items approximated fair value.
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, Financial Accounting Standards Board (“FASB”) ASC Topic 820-10-35 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements).
	Level 1—Valuations based on quoted prices for identical assets and liabilities in active markets.
	Level 2—Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.
	Level 3—Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.
	The application of the three levels of the fair value hierarchy under Topic 820-10-35 to our assets and liabilities are described below:
			Fair Value Measurements
			Level 1		Level 2		Level 3		Total
	Assets
	Website development		$	-	$	-	$	261,340	$	261,340
	Intangible assets			-		-		1,339		1,339
	Total		$	-	$	-	$	262,679	$	262,679
	Liabilities
	Deferred Revenues		$	2,075	$	-	$	-	$	2,075
	Derivative Liability			-		-		1,062,141		1,062,141
	Total		$	2,791	$	-	$	1,535,431	$	1,064,216
	Impairment of Long Lived Assets
	In accordance with Accounting Standards Codification (“ASC”) 360-10, Accounting for the Impairment or Disposal of Long-Lived Assets, long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. ASC 360-10 relates to assets that can be amortized and the life can be determinable. The Company reviews property and equipment and other long-lived assets for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability is measured by comparison of the asset’s carrying amount to future undiscounted net cash flows the assets are expected to generate.  Cash flow forecasts are based on trends of historical performance and management's estimate of future performance, giving consideration to existing and anticipated competitive and economic conditions.  If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future cash flows arising from the assets or their fair values, whichever is more determinable.
Inventory
Inventories are stated at the lower of cost or market value.  Cost is determined by the first-in, first-out basis and market being determined as the lower of replacement cost or net realizable value. The Company records inventory write-downs for estimated obsolescence of unmarketable inventory based upon assumptions about future demand and market conditions.  For the years ended December 31, 2013 and 2012, the Company did not have any inventory write downs.
Net Loss per Share
Basic and diluted loss per share amounts are computed based on net loss divided by the weighted average number of common shares outstanding. Warrants to purchase 3,037,546 common shares were not included in the computation of diluted loss per share because the assumed conversion and exercise would be anti-dilutive for the year ending December 31, 2013.
Management Estimates
The presentation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates.
Stock Based Compensation
The Company accounts for all compensation related to stock, options or warrants using a fair value based method whereby compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. The Company uses the Black-Scholes pricing model to calculate the fair value of options and warrants issued to both employees and non-employees. Stock issued for compensation is valued using the market price of the stock on the date of the related agreement.

ACCOUNTS_RECEIVABLE

ACCOUNTS RECEIVABLE	12 Months Ended
	Dec. 31, 2013
Accounts Receivables [Abstract]	'
ACCOUNTS RECEIVABLE	'
	2.  ACCOUNTS RECEIVABLE
	Due to the collection history of the Company, the Company does not maintain an allowance for doubtful accounts.  Recognition of a specific uncollectible account is written directly against the invoice in accounts receivable and expensed in the current period.

WEBSITE_DEVELOPMENT

WEBSITE DEVELOPMENT	12 Months Ended
	Dec. 31, 2013
Website Development [Abstract]	'
WEBSITE DEVELOPMENT	'
	3.   WEBSITE DEVELOPMENT
	Website development consists of the following:
		December 31,			December 31,
		2013			2012
	Website development	$	224,946		$	62,946
	Additional development		99,340			162,00
	Accumulated amortization		(62,946	)		(57,701	)
	Net website development	$	261,340		$	167,245
	During May 2012 the Company began redesigning its website.  The Company anticipates that the redesign will be completed by March 2014.
	Amortization is calculated over a three-year period. Amortization expense for the years ending December 31, 2013 and 2012 is $5,245 and $20,961, respectively.

FURNITURE_AND_EQUIPMENT

FURNITURE AND EQUIPMENT	12 Months Ended
	Dec. 31, 2013
Furniture and Equipment [Abstract]	'
FURNITURE AND EQUIPMENT	'
	4. FURNITURE AND EQUIPMENT
	Furniture and equipment consists of the following:
		December 31,			December 31,
		2013			2012
	Computers and equipment	$	169,286		$	169,286
	Furniture and fixtures		38,618			38,618
	Subtotal		207,904			207,904
	Less: accumulated depreciation		(207,491	)		(206,375	)
	Net furniture and equipment	$	413		$	1,529
	Depreciation is calculated by using the straight-line method over the estimated useful life.   Depreciation expense totaled $1,117 and $8,749 for the year ended December 31, 2013 and 2012, respectively.

CONVERTIBLE_DEBEBTURE_RELATED_

CONVERTIBLE DEBEBTURE - RELATED PARTY	12 Months Ended
	Dec. 31, 2013
Convertible Debebture - Related Party [Abstract]	'
CONVERTIBLE DEBEBTURE - RELATED PARTY	'
	5. CONVERTIBLE DEBEBTURE – RELATED PARTY
	The Company entered into two 10% Secured Convertible Debentures with a significant shareholder.  The debentures carry a one year term.  The debentures were issued in the amount of $50,000 on November 4, 2013 and $60,000 on December 17, 2013.  Both debentures have a conversion feature at a share price of $0.10.  The Company recognized a beneficial conversion feature (BCF) due to the intrinsic value of the conversion rate compared to the market price of the common stock as of the grant date. A discount is computed based on the share value at the time of issuance and amortized over the period of the debenture.
		December 31,			December 31,
		2013			2012
	Convertible debenture – related party	$	111,013		$	-
	Beneficial conversion feature		(101,836	)		-
	Convertible debenture, net of BCF	$	9,177		$	-

WARRANT_LIABILITY

WARRANT LIABILITY	12 Months Ended
	Dec. 31, 2013
Warrant Liability [Abstract]	'
WARRANT LIABILITY	'
	6. WARRANT LIABILITY
	In connection with certain securities purchase agreements entered into during the third quarter 2011 and the second quarter 2012 (see Note 7), the Company granted warrants with ratchet provisions. The warrants contain an expiration date of four years from the date of grant. During the first two years of grant, if the Company issues any additional shares of common stock at a price per share less than the exercise price in effect, the exercise price will be adjusted to equal the average price per share received by the Company for the additional shares issued. After the first two years, if the Company issues any additional shares of common stock at a price per share less than the exercise price in effect, the exercise price will be adjusted using a formula based on the existing exercise price, the outstanding shares before and after the issuance of such shares, and the average price during the issuance of such shares. In addition to the exercise price adjustment, the number of shares upon exercise of the warrants is also subject to adjustment.
	Upon grant, the Company assesses the fair value of the warrants using the Black Scholes pricing model and records a warrant liability for the value. The Company then assesses the fair value of the warrants quarterly based on the Black Scholes Model and increases or decreases the warrant liability to the new value, and records a corresponding gain or loss. The Company uses expected volatility based primarily on historical volatility using weekly pricing observations for recent periods that correspond to the expected life of the warrants. The risk-free interest rate is based on U.S. Treasury securities rates.
	Due to the ratchet provisions, the Company treats the warrants as a derivative liability in accordance with the provisions of ASC 815 “Derivatives and Hedging” (ASC 815). ASC 815 applies to any freestanding financial instruments or embedded features that have the characteristics of a derivative and to any freestanding financial instruments that potentially settle in an entity’s own common stock.
	As of December 31, 2013, these warrants include the following:
	Warrants granted during July 2011 in connection with the sale of 35,461 shares of common stock with the right to originally purchase up to 35,461 shares of the Company’s common stock with an original exercise price of $2.50. Due to the issuance of the Company’s common stock in April 2012, the exercise price was adjusted to $0.50 and the number of shares to 1,808,511. Fair value was determined using the following variables:
		Grant Date			31-Dec-13			31-Dec-12
	Risk-free interest rate at grant date		1.21	%		1.27	%		0.54	%
	Expected stock price volatility		194.9	%		189.65	%		187	%
	Expected dividend payout		-			-			-
	Expected option in life-years		4			1.5			2.5
	Warrants granted during April 2012 in connection with the sale of 100,000 shares of the Company’s preferred stock to a significant shareholder and brother of the Chief Executive Officer with the right to purchase up to 200,000 shares of the Company’s common stock with an exercise price of $0.50. Fair value was determined using the following variables:
		Grant Date			31-Dec-13
	Risk-free interest rate at grant date		0.47	%		1.27	%
	Expected stock price volatility		137.8	%		189.65	%
	Expected dividend payout		-			-
	Expected option in life-years		3.75			2
	Warrants granted during April 2012 in connection with the sale of 1,000,000 shares of the Company’s common stock with an exercise price of $0.50.
		Grant Date			31-Dec-13
	Risk-free interest rate at grant date		0.47	%		1.27	%
	Expected stock price volatility		137.8	%		18965	%
	Expected dividend payout		-			-
	Expected option in life-years		3.75			2.25
	Transactions involving warrants with ratchet provisions are as follows:
		Number of Warrants			Weighted-Average Price Per Share
	Outstanding at December 31, 2011		1,200,000		$	0.5
	Granted
	Exercised
	Canceled or expired
	Additional due to ratchet trigger		1,808,511			0.5
	Outstanding at December 31, 2012		3,008,511			0.5
	Granted
	Exercised
	Canceled or expired
	Addition due to ratchet trigger
	Outstanding at December 31, 2013		3,008,511		$	0.5
	As of December 31, 2013 and December 31, 2012, the warrant liability consisted of the following:
		December 31,			December 31,
		2013			2012
	Warrant liability (beginning balance)	$	5,618,819		$	111,636
	Additional liability due to new grants					5,078,052
	Loss(gain) on changes in fair market value of warrant liability		-4,556,678			429,131
	Net warrant liability	$	1,062,141		$	5,618,819
	Change in fair market value of warrant liability resulted in a gain totaling $2,366,218 and a loss of $429,131 for the years ended December 31, 2013 and 2012, respectively.

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
EQUITY	'
	7. EQUITY
	Common Stock
	On October 8, 2012, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of Nevada, pursuant to which (i) the Company effected a 5,000-to-1 reverse split of its common stock and (ii) the number of authorized shares of the Company’s common stock decreased from 75,000,000,000 to 100,000,000. The market effective date of the reverse split was October 9, 2012.  The effect of the stock split has been applied retroactively.   On December 19, 2013 the Company increased its authorized shares of common stock from 100,000,000 to 500,000,000
	2012
	On March 1, 2012, the Company issued 10,714 shares of common stock to a consultant. The market value of the shares was $42,859,
	On April 18, 2012, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which, on April 18, 2012, the Company sold 1,000,000 shares of common stock for an aggregate purchase price of $500,000, and the Company issued four-year warrants to purchase 1,000,000 shares of common stock to the investors with an exercise price of $0.50. The investors were purchasers under the Company’s Securities Purchase Agreements entered into in July 2011.
	On April 23, 2012, the Company issued an aggregate of 7,980,133 shares of common stock to certain shareholders of the Company, in accordance with anti-dilution rights held by such shareholders, including 5,383,594 shares to Lyle Hauser valued at par $539, 1,632,000 shares to Kevin Hauser valued at fair market value for compensation expense of $9,792,000, and 964,539 shares valued at par $96 to purchasers under Securities Purchase Agreements entered into by the Company in July 2011. Lyle Hauser is the Company’s largest shareholder and the brother of Kevin Hauser, the Company’s chief executive officer.
	On May 15, 2012, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which, on May 15, 2012, the Company sold 600,000 shares of common stock for an aggregate purchase price of $300,000, and the Company issued four-year warrants to purchase 600,000 shares of common stock to the investors with an exercise price of $0.50. The investors were purchasers under the Company’s Securities Purchase Agreements entered into in July 2011.
	On June 26, 2012, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which, on June 26, 2012, the Company sold 200,000 shares of common stock for an aggregate purchase price of $100,000, and the Company issued four-year warrants to purchase 200,000 shares of common stock to the investors with an exercise price of $0.50. The investors were purchasers under the Company’s Securities Purchase Agreements entered into in July 2011.  The Company issued 100,000 shares on July 18, 2012 and the remaining 100,000 shares on November 14, 2012.
	On July 16, 2012, the Company issued 24,000 shares of common stock to a consultant in the amount of $60,000.
	On September 20, 2012, the Company sold 100,000 shares of common stock for a purchase price of $50,000.   The shares were issued on November 14, 2012
	On August 24, 2012, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which, the Company sold 500,000 shares of common stock for an aggregate purchase price of $250,000.
	2013
	On January 17, 2013 the Company entered into a Securities Purchase Agreement pursuant to which, the Company sold 400,000 shares of common stock for an aggregate purchase price of $200,000
	On April 15, 2013, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which the Company sold 2,000,000 shares of common stock for an aggregate purchase price of $400,000.
	On May 1, 2013 the Company issued an aggregate of 11,872,281shares of common stock to purchasers under the securities purchase agreements entered into by the Company in July 2011 and April 2012 pursuant to anti-dilution rights held by such purchasers.
	On August 27, 2013, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which, the Company sold 42,743 shares of common stock for an aggregate purchase price of $29,920.
	On September 23, 2013, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which, the Company sold 21,429 shares of common stock for an aggregate purchase price of $15,000.
	On December 17, 2013, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which, the Company sold 2,000,000 shares of common stock for an aggregate purchase price of $40,000.  The shares are currently unissued.  In connection with this sale, the Company will issue an aggregate of 150,129,655 shares of common stock to existing stockholders for no additional consideration pursuant to anti-dilution rights held by such stockholders. These shares have not yet been issued.
	On December 20, 2013, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which, the Company sold 15,000,000 shares of common stock for an aggregate purchase price of $300,000.
	Preferred Stock
	On April 10, 2012, the Company filed a certificate of designation of Series B Preferred Stock (the “Series B Certificate of Designation”) with the Secretary of State of Nevada, pursuant to which 100,000 shares of the Company’s preferred stock were designated as Series B Convertible Preferred Stock (the “Series B Preferred Stock”).  Pursuant to the Series B Certificate of Designation, the Series B Preferred Stock:
	●	Has a liquidation preference over the common stock equal to the stated value of $1.00 per share.
	●	Votes as a single class with the common stock and entitles its holders, for each share of Series B Preferred Stock, to cast such number of votes equal to 0.00051% of the total number of votes entitled to be cast. Accordingly, a holder of all 100,000 shares of Series B Preferred Stock will have the right to cast 51% of the total number of votes entitled to be cast.
	●	Will automatically convert into common stock at a ratio of 2 shares of common stock for each share of Series B Preferred Stock, effective upon the Company’s filing of a certificate of amendment to its articles of incorporation.
	On April 12, 2012, the Company entered into a securities purchase agreement with Lyle Hauser (the “Preferred Stock Investor”). Lyle Hauser is the Company’s largest shareholder and the brother of Kevin Hauser, the Company’s chief executive officer. Pursuant to the purchase agreement, on April 12, 2012, the Company sold 100,000 shares of Series B Preferred Stock to the Preferred Stock Investor for an aggregate purchase price of $100,000, and the Company issued four-year warrants to purchase 200,000 shares of common stock to the Preferred Stock Investor with an exercise price of $0.50. On April 23, 2012, 100,000 Series B Preferred shares were converted to 200,000 shares of common stock
	Stock Options
	2006 Incentive Stock Plan
	In January 2006, the Board of Directors of the Company approved an Incentive Stock Plan, pursuant to which they have initially reserved 2,000 shares of common Stock for issuance. Under the 2006 Incentive Stock, the Board has granted an aggregate of 1,128 options to employees pursuant to certain employment agreements. All previously granted options have expired unexercised.
	2008 Amended and Restated Incentive Stock Plan
	In November 2008, our Board of Directors adopted the 2008 Equity Incentive Plan and subsequently amended it in January 2009, June 2009 and July 2009 (the “2008 Plan”). The purpose of the 2008 Plan was to provide an incentive to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons into our development and financial success. Under the 2008 Plan, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Code, non-qualified stock options, stock appreciation rights, performance shares, restricted stock and long term incentive awards. The 2008 Plan will be administered by our Board of Directors until such time as such authority has been delegated to a committee of the board of directors.
	2010 Incentive Stock Plan
	In December 2009, our Board of Directors adopted the 2010 Equity Incentive Plan (the “2010 Plan”). The purpose of the 2010 Plan was to provide an incentive to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons into our development and financial success. Under the 2010 Plan, we are authorized to issue incentive stock options intended to qualify under Section 422 of the Code, non-qualified stock options, stock appreciation rights, performance shares, restricted stock and long term incentive awards. The 2010 Plan will be administered by our Board of Directors until such time as such authority has been delegated to a committee of the Board of Directors.
	Other Warrants
	During the first quarter of 2008 the Company awarded 35 Common Stock warrants, at an exercise price of $2800 per share, to former Board members at the quoted stock price on the effective date of the awards. The warrants have an expiration date of five years from the issue date and contain provisions for a cash exercise. The estimated value of the compensatory warrants granted to non-employees in exchange for services and financing expenses was determined using the Black-Scholes pricing model and the following assumptions:
	Risk-free interest rate at grant date			4.75	%
	Expected stock price volatility			155	%
	Expected dividend payout			--
	Expected option in life-years			5
	On June 22, 2011, the Company awarded 2,000 Common Stock warrants, at an exercise price of $50 per share, to consultants for services at the quoted stock price on the effective date of the awards. The warrants have an expiration date of four years from the issue date and contain provisions for a cash exercise. The estimated value of the compensatory warrants granted to non-employees in exchange for services and financing expenses was determined using the Black-Scholes pricing model and the following assumptions listed below:
	On July 28, 2011, the Company awarded 27,000 Common Stock Warrants, at an exercise price of $25 per share to consultants for services at the quoted stock price on the effective date of the awards.  The warrants have an expiration date of three years from the issue date and contain provisions for a cash exercise.  The estimated value of the compensatory warrants granted to non-employees in exchange for services was determined using the Black-Scholes pricing model and the assumptions listed below.
	Risk-free interest rate at grant date			0.39	%
	Expected stock price volatility			172.1	%
	Expected dividend payout			--
	Expected option in life-years			4
	Transactions involving warrants are summarized as follows:
			Number of Warrants				Weighted-Average Price Per Share
	Outstanding at December 31, 2011			29,035				30.07
	Granted			-				-
	Exercised			-				-
	Canceled or expired			-				-
	Outstanding at December 31, 2012			29,035			$	30.07
	Granted			-				-
	Exercised			-35				28
	Canceled or expired			-				-
	Outstanding at September30, 2013			29,000			$	48.27
	Warrants Outstanding
									Weighted
									Average
									Remaining
	Exercise					Number			Contractual
	Prices					Outstanding			Life (years)
		$	25				2,000			1
		50				27,000			2.25
						29,000			2.43

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	8. RELATED PARTY TRANSACTIONS
	On December 17, 2013, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which, the Company sold 2,000,000 shares of common stock for an aggregate purchase price of $40,000.  The shares are currently unissued
	During the fourth quarter of 2013, the Company sold two 10% Secured Convertible Promissory Notes from a significant shareholder in the amount of $110,000.   The notes have a one year term.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	9.  SUBSEQUENT EVENTS
	On January 27, 2014, Kevin Hauser resigned as President, Chairman, and Chief Executive Officer of MedeFile International, Inc. (the “Company”). Mr. Hauser will continue to support the Company’s new business development activities on a consulting basis as a member of MedeFile’s sales and marketing team.
	On January 28, 2014, Niquana Noel was appointed Chairwoman, President and Chief Executive Officer of the Company.

BASIS_OF_PRESENTATION_AND_NATU1

BASIS OF PRESENTATION AND NATURE OF BUSINESS OPERATIONS (Policies)	12 Months Ended
	Dec. 31, 2013
Basis of Presentation and Nature of Business Operations [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying financial statements present on a consolidated basis the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation
Nature of Business Operations	'
	Nature of Business Operations
	Medefile International, Inc. has developed and globally markets a proprietary, patient-centric, Internet-enabled Personal Health Record (iPHR) system for gathering, digitizing, maintaining, accessing and sharing an individual’s actual medical records. Medefile's goal is to revolutionize the medical industry by bringing patient-centric digital technology to the business of medicine. Medefile intends to accomplish its objective by providing individuals with a simple and secure way to access their lifetime of actual medical records in an efficient and cost-effective manner. Medefile's products and services are designed to provide healthcare providers with the ability to reference their patients’ actual past medical records, thereby ensuring the most accurate treatment and services possible while simultaneously reducing redundant procedures.
	Interoperable with most electronic medical record systems utilized by physician practices, clinics, hospitals and other care providers, the highly secure, feature-rich MedeFile iPHR solution has been designed to gather all of its members’ actual medical records on behalf of each member, and create a single, comprehensive Electronic Health Record (EHR). The member can access his/her records 24-hours a day, seven days a week – or authorize a third party user – on any web-enabled device (PC, cell phone, PDA, e-reader, et al), as well as the portable MedeFile flash drive/keychain or branded UBS-bracelet.
	By subscribing to the MedeFile system, members empower themselves to take control of their own health and well-being, and empower their healthcare providers to make sound and lifesaving decisions with the most accurate, up-to-date medical information available.  In addition, with MedeFile, members enjoy the peace of mind that comes from knowing that their medical records are protected from fire, natural disaster, document misplacement or the closing of a medical or dental practice.
	MedeFile believes it enjoys a number of competitive advantages over other firms within the medical records marketplace, including:
	●	MedeFile has developed products and services geared to the patient, while containing the depth and breadth of information required by treating physicians and medical personnel.
	●	MedeFile does all the work of collecting and updating medical information on an ongoing basis; the function of our products’ dependence on the patient taking action is minimal – particularly when compared to patient action required to support competing solutions.
	●	MedeFile provides a complete medical record. Other companies claim complete longitudinal records, but in reality only provide histories (usually completed by the member/patient), which are by no means complete or necessarily accurate records.
	●	MedeFile provides a coherent mix of services and products that are intended to improve the quality of healthcare by enabling the patient to manage and access the information normally retained by doctors and other care providers.
Going Concern	'
	Going Concern
	The accompanying financial statements have been prepared contemplating a continuation of the Company as a going concern. However, the Company has reported a net income of $1,427,251 for the year ended December 31, 2013.  During the comparable year ended 2012, the Company had a net loss of $11,404,925, as a direct result of the change in valuation of the Company’s warrant derivative. The Company had an accumulated deficit of $27,696,097 as of December 31, 2013.  The Company has negative working capital of $786,169 as of December 31, 2013.
	The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The operating losses raise substantial doubt about the Company's ability to continue as a going concern. The Company's ability to obtain additional financing depends on the availability of its borrowing capacity, the success of its growth strategy and its future performance, each of which is subject to general economic, financial, competitive, legislative, regulatory, and other factors beyond the Company's control.
	We will need additional investments in order to continue operations to cash flow break even. Additional investments are being sought, but we cannot guarantee that we will be able to obtain such investments. Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms.
	However, the trading price of our common stock could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek alternative financing. Further, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we will have to curtail our operations.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	For purposes of these financial statements, cash and cash equivalents includes highly liquid debt instruments with maturity of less than three months.
Concentrations of Credit Risk	'
	Concentrations of Credit Risk
	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.  Currently our operating account is not above the FDIC limit.
Advertising	'
	Advertising
	The Company follows the policy of charging the costs of advertising to expense as incurred. The Company incurred advertising costs for the year ended December 31, 2013 and 2012 of approximately $0 and $0 respectively.
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
	The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. A valuation allowance is established against deferred tax assets that do not meet the criteria for recognition. In the event the Company were to determine that it would be able to realize deferred income tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.
	The Company follows the accounting guidance which provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more-likely-than-not recognition threshold at the effective date to be recognized initially and in subsequent periods. Also included is guidance on measurement, recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives being 3 years up to 10 years.
Trademark Costs	'
	Trademark Costs
	Trademark costs incurred in the registration and acquisition of trademarks and trademark rights are capitalized. These costs will be amortized over the legal life of the related trademark once the trademark is awarded. The Company performs an annual review of its identified intangible assets to determine if facts and circumstances exist which indicate that the useful life is shorter than originally estimated or that the carrying amount of the assets may not be recoverable.
	The Company expenses all software costs associated with the conceptual formulation and evaluation of alternatives until the application development stage has been reached. Costs to improve or support the technology are expensed as these costs are incurred.
Website Development	'
	Website Development
	The Company's policy is to capitalize website development costs at original cost and amortize the balance over the life of the product.  The life of website is determined at completion of the project. The Company reviews the amounts capitalized for impairment whenever events or circumstances indicate that the carrying amounts of the assets may not be recoverable.
	The Company expenses all development costs associated with the conceptual formulation and evaluation of alternatives until the application development stage has been reached. Costs to improve or support the technology are expensed as these costs are incurred.
Revenue Recognition	'
	Revenue Recognition
	The Company generates revenue from licensing the right to utilize its proprietary software for the storage and distribution of healthcare information to individuals and affinity groups. For revenue from product sales, the Company recognizes revenue on four basic criteria which must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
Deferred Revenue	'
	Deferred Revenue
	The Company generally receives subscription fees for its services. From time to time, the Company will receive quarterly or annual subscriptions paid in advance and deferred revenue is recorded at that time. The deferred revenue is amortized into revenue on a pro- rata basis each month. Customers with quarterly or annual subscriptions may cancel their subscriptions and request a refund for future months' revenues at any time. Therefore, a liability is recorded to reflect the amounts that are potentially refundable. At December 31, 2013 and December 31, 2012, deferred revenue totaled $2,075 and$4,313, respectively.
Reclassifications	'
	Reclassifications
	Certain reclassifications have been made in prior periods financial statements to conform to classifications used in the current period.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	There are no recent accounting pronouncements that are expected to have a material effect on the Company’s financial statements.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Cash and Equivalents, Deposits In-Transit, Receivables, Prepaid and Other Current Assets, Accounts Payable, Accrued Salaries and Wages and Other Current Liabilities
	The carrying amounts of these items approximated fair value.
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, Financial Accounting Standards Board (“FASB”) ASC Topic 820-10-35 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements).
	Level 1—Valuations based on quoted prices for identical assets and liabilities in active markets.
	Level 2—Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.
	Level 3—Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.
	The application of the three levels of the fair value hierarchy under Topic 820-10-35 to our assets and liabilities are described below:
			Fair Value Measurements
			Level 1		Level 2		Level 3		Total
	Assets
	Website development		$	-	$	-	$	261,340	$	261,340
	Intangible assets			-		-		1,339		1,339
	Total		$	-	$	-	$	262,679	$	262,679
	Liabilities
	Deferred Revenues		$	2,075	$	-	$	-	$	2,075
	Derivative Liability			-		-		1,062,141		1,062,141
	Total		$	2,791	$	-	$	1,535,431	$	1,064,216
Impairment of Long Lived Assets	'
	Impairment of Long Lived Assets
	In accordance with Accounting Standards Codification (“ASC”) 360-10, Accounting for the Impairment or Disposal of Long-Lived Assets, long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. ASC 360-10 relates to assets that can be amortized and the life can be determinable. The Company reviews property and equipment and other long-lived assets for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability is measured by comparison of the asset’s carrying amount to future undiscounted net cash flows the assets are expected to generate.  Cash flow forecasts are based on trends of historical performance and management's estimate of future performance, giving consideration to existing and anticipated competitive and economic conditions.  If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future cash flows arising from the assets or their fair values, whichever is more determinable.
Inventory	'
	Inventory
	Inventories are stated at the lower of cost or market value.  Cost is determined by the first-in, first-out basis and market being determined as the lower of replacement cost or net realizable value. The Company records inventory write-downs for estimated obsolescence of unmarketable inventory based upon assumptions about future demand and market conditions.  For the years ended December 31, 2013 and 2012, the Company did not have any inventory write downs.
Net Loss per Share	'
	Net Loss per Share
	Basic and diluted loss per share amounts are computed based on net loss divided by the weighted average number of common shares outstanding. Warrants to purchase 3,037,546 common shares were not included in the computation of diluted loss per share because the assumed conversion and exercise would be anti-dilutive for the year ending December 31, 2013.
Management Estimates	'
	Management Estimates
	The presentation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates.
Stock-Based Compensation	'
	Stock Based Compensation
	The Company accounts for all compensation related to stock, options or warrants using a fair value based method whereby compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. The Company uses the Black-Scholes pricing model to calculate the fair value of options and warrants issued to both employees and non-employees. Stock issued for compensation is valued using the market price of the stock on the date of the related agreement.

BASIS_OF_PRESENTATION_AND_NATU2

BASIS OF PRESENTATION AND NATURE OF BUSINESS OPERATIONS (Tables)	12 Months Ended
	Dec. 31, 2013
Basis of Presentation and Nature of Business Operations [Abstract]	'
Schedule of three levels of the fair value hierarchy to assets and liabilities	'
		Fair Value Measurements
			Level 1		Level 2		Level 3		Total
	Assets
	Website development		$	-	$	-	$	261,340	$	261,340
	Intangible assets			-		-		1,339		1,339
	Total		$	-	$	-	$	262,679	$	262,679
	Liabilities
	Deferred Revenues		$	2,075	$	-	$	-	$	2,075
	Derivative Liability			-		-		1,062,141		1,062,141
	Total		$	2,791	$	-	$	1,535,431	$	1,064,216

WEBSITE_DEVELOPMENT_Tables

WEBSITE DEVELOPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
Website Development [Abstract]	'
Schedule of website development	'
		December 31,				December 31,
		2013				2012
	Website development		$	224,946			$	62,946
	Additional development			99,340				162,00
	Accumulated amortization			(62,946	)			(57,701	)
	Net website development		$	261,340			$	167,245

FURNITURE_AND_EQUIPMENT_Tables

FURNITURE AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
Furniture and Equipment [Abstract]	'
Schedule of furniture and equipment	'
		December 31,				December 31,
		2013				2012
	Computers and equipment		$	169,286			$	169,286
	Furniture and fixtures			38,618				38,618
	Subtotal			207,904				207,904
	Less: accumulated depreciation			(207,491	)			(206,375	)
	Net furniture and equipment		$	413			$	1,529

CONVERTIBLE_DEBEBTURE_RELATED_1

CONVERTIBLE DEBEBTURE - RELATED PARTY (Tables)	12 Months Ended
	Dec. 31, 2013
Convertible Debebture - Related Party [Abstract]	'
Schedule of convertible debentures	'
		December 31,				December 31,
		2013				2012
	Convertible debenture – related party		$	111,013			$	-
	Beneficial conversion feature			(101,836	)			-
	Convertible debenture, net of BCF		$	9,177			$	-

WARRANT_LIABILITY_Tables

WARRANT LIABILITY (Tables)	12 Months Ended
	Dec. 31, 2013
Class of Warrant or Right [Line Items]	'
Schedule of transactions involving warrants	'
		Number of Warrants				Weighted-Average Price Per Share
	Outstanding at December 31, 2011			1,200,000			$	0.5
	Granted
	Exercised
	Canceled or expired
	Additional due to ratchet trigger			1,808,511				0.5
	Outstanding at December 31, 2012			3,008,511				0.5
	Granted
	Exercised
	Canceled or expired
	Addition due to ratchet trigger
	Outstanding at December 31, 2013			3,008,511			$	0.5
Schedule of warrant liability	'
		December 31,				December 31,
		2013				2012
	Warrant liability (beginning balance)		$	5,618,819			$	111,636
	Additional liability due to new grants							5,078,052
	Loss(gain) on changes in fair market value of warrant liability			-4,556,678				429,131
	Net warrant liability		$	1,062,141			$	5,618,819
Warrants granted during July 2011	'
Class of Warrant or Right [Line Items]	'
Schedule of fair value assumptions for warrants	'
		Grant Date				31-Dec-13				31-Dec-12
	Risk-free interest rate at grant date			1.21	%			1.27	%		0.54	%
	Expected stock price volatility			194.9	%			189.65	%		187	%
	Expected dividend payout			-				-			-
	Expected option in life-years			4				1.5			2.5
Warrants granted during April 2012	'
Class of Warrant or Right [Line Items]	'
Schedule of fair value assumptions for warrants	'
			Grant Date				31-Dec-13
	Risk-free interest rate at grant date			0.47	%			1.27	%
	Expected stock price volatility			137.8	%			189.65	%
	Expected dividend payout			-				-
	Expected option in life-years			3.75				2
Warrants granted during April 2012 | Shareholder and Brother of Chief Executive Officer	'
Class of Warrant or Right [Line Items]	'
Schedule of fair value assumptions for warrants	'
		Grant Date				31-Dec-13
	Risk-free interest rate at grant date			0.47	%			1.27	%
	Expected stock price volatility			137.8	%			18965	%
	Expected dividend payout			-				-
	Expected option in life-years			3.75				2.25

EQUITY_Tables

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Schedule of estimated value of the compensatory warrants granted to non-employees in exchange for services and financing expenses	'
	Risk-free interest rate at grant date			4.75	%
	Expected stock price volatility			155	%
	Expected dividend payout			--
	Expected option in life-years			5
Schedule of estimated value of the compensatory warrants granted to non-employees in exchange for services	'
	Risk-free interest rate at grant date			0.39	%
	Expected stock price volatility			172.1	%
	Expected dividend payout			--
	Expected option in life-years			4
Schedule of warrants transactions	'
		Number of Warrants				Weighted-Average Price Per Share
	Outstanding at December 31, 2011			29,035				30.07
	Granted			-				-
	Exercised			-				-
	Canceled or expired			-				-
	Outstanding at December 31, 2012			29,035			$	30.07
	Granted			-				-
	Exercised			-35				28
	Canceled or expired			-				-
	Outstanding at September30, 2013			29,000			$	48.27
	Warrants Outstanding
									Weighted
									Average
									Remaining
	Exercise					Number			Contractual
	Prices					Outstanding			Life (years)
		$	25				2,000			1
			50				27,000			2.25
							29,000			2.43

BASIS_OF_PRESENTATION_AND_NATU3

BASIS OF PRESENTATION AND NATURE OF BUSINESS OPERATIONS - Fair value hierarchy to our assets and liabilities (Details) (USD $)	Dec. 31, 2013
Level 1	'
Assets	'
Merchant Service Reserves	'
Intangible assets	'
Total	'
Liabilities	'
Deferred Revenues	2,075
Derivative Liability	'
Total	2,791
Level 2	'
Assets	'
Merchant Service Reserves	'
Intangible assets	'
Total	'
Liabilities	'
Deferred Revenues	'
Derivative Liability	'
Total	'
Level 3	'
Assets	'
Merchant Service Reserves	261,340
Intangible assets	1,339
Total	262,679
Liabilities	'
Deferred Revenues	'
Derivative Liability	1,062,141
Total	1,535,431
Total Fair Value	'
Assets	'
Merchant Service Reserves	261,340
Intangible assets	1,339
Total	262,679
Liabilities	'
Deferred Revenues	2,075
Derivative Liability	1,062,141
Total	$1,064,216

BASIS_OF_PRESENTATION_AND_NATU4

BASIS OF PRESENTATION AND NATURE OF BUSINESS OPERATIONS (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Basis of Presentation and Nature of Business Operations [Abstract]	'	'
Income (loss)	$1,427,251	($11,404,925)
Accumulated deficit	-27,696,097	-29,123,348
Net working capital	786,169	'
Advertising costs	0	0
Deferred revenues	$2,075	$4,313

BASIS_OF_PRESENTATION_AND_NATU5

BASIS OF PRESENTATION AND NATURE OF BUSINESS OPERATIONS (Detail Textuals 1)	12 Months Ended
	Dec. 31, 2013
Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful lives	'10 years
Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful lives	'3 years

BASIS_OF_PRESENTATION_AND_NATU6

BASIS OF PRESENTATION AND NATURE OF BUSINESS OPERATIONS (Detail Textuals 2) (Warrant)	12 Months Ended
	Dec. 31, 2013
Warrant	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'
Antidilutive securities excluded from computation of earnings per share amount	3,037,546

WEBSITE_DEVELOPMENT_Summary_of

WEBSITE DEVELOPMENT - Summary of website development (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Accumulated amortization	($62,946)	($57,701)
Net website development	261,340	167,245
Website development	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross website development	224,946	62,946
Additional development	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross website development	$99,340	$16,200

WEBSITE_DEVELOPMENT_Detail_Tex

WEBSITE DEVELOPMENT (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Website Development [Abstract]	'	'
Amortization	$5,245	$20,982
Finite lived intangible assets, Amortization period	'3 years	'

FURNITURE_AND_EQUIPMENT_Summar

FURNITURE AND EQUIPMENT - Summary of furniture and equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Subtotal	$207,904	$207,904
Less: accumulated depreciation	-207,491	-206,375
Net furniture and equipment	413	1,529
Computers and equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Subtotal	169,286	169,286
Furniture and fixtures	'	'
Property, Plant and Equipment [Line Items]	'	'
Subtotal	$38,618	$38,618

FURNITURE_AND_EQUIPMENT_Detail

FURNITURE AND EQUIPMENT (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Furniture and Equipment [Abstract]	'	'
Depreciation	$1,116	$8,749

CONVERTIBLE_DEBEBTURE_RELATED_2

CONVERTIBLE DEBEBTURE - RELATED PARTY (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Convertible Debebture - Related Party [Abstract]	'	'
Convertible debenture - related party	$111,013	'
Beneficial conversion feature	-101,836	'
Convertible debenture, net of BCF	$9,177	'

CONVERTIBLE_DEBEBTURE_RELATED_3

CONVERTIBLE DEBEBTURE - RELATED PARTY (Details Textual) (Two 10% Secured Convertible Debentures [Member], USD $)	1 Months Ended	0 Months Ended
	Dec. 17, 2013	Nov. 04, 2013
Two 10% Secured Convertible Debentures [Member]	'	'
Short-term Debt [Line Items]	'	'
Terms of conversion feature	'one year	'one year
Convertible debenture Issued	$60,000	$50,000
Convertible conversion Price	$0.10	$0.10

WARRANT_LIABILITY_Summary_of_f

WARRANT LIABILITY - Summary of fair value of warrants (Details)	1 Months Ended	12 Months Ended		1 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended
	Jul. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Apr. 30, 2012	Dec. 31, 2013	Apr. 30, 2012	Dec. 31, 2013
	Warrants granted during July 2011	Warrants granted during July 2011	Warrants granted during July 2011	Warrants granted during April 2012	Warrants granted during April 2012	Warrants granted during April 2012	Warrants granted during April 2012
						Shareholder and Brother of Chief Executive Officer	Shareholder and Brother of Chief Executive Officer
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Risk-free interest rate at grant date	1.21%	1.27%	0.54%	0.47%	1.27%	0.47%	1.27%
Expected stock price volatility	194.90%	189.65%	187.00%	137.80%	189.65%	137.80%	189.65%
Expected dividend payout	'	'	'	'	'	'	'
Expected option in life-years	'4 years	'1 year 6 months	'2 years 6 months	'3 years 9 months	'2 years 3 months	'3 years 9 months	'2 years

WARRANT_LIABILITY_Summary_of_t

WARRANT LIABILITY - Summary of transactions involving warrants (Details 1) (Warrants with ratchet provisions)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Warrants with ratchet provisions	'	'
Warrant Outstanding [Roll Forward]	'	'
Number of Warrants, Outstanding	3,008,511	1,200,000
Number of Warrants, Granted	'	'
Number of Warrants, Exercised	'	'
Number of Warrants, Canceled or expired	'	'
Additional due to ratchet trigger	'	1,808,511
Number of Warrants, Outstanding	3,008,511	3,008,511
Warrants Outstanding Weighted Average Price Per Share [Roll Forward]	'	'
Weighted-Average Price Per Share, Outstanding	0.5	0.5
Weighted-Average Price Per Share, Granted	'	'
Weighted-Average Price Per Share, Exercised	'	'
Weighted-Average Price Per Share, Canceled or expired	'	'
Additional due to ratchet trigger	'	0.5
Weighted-Average Price Per Share, Outstanding	0.5	0.5

WARRANT_LIABILITY_Summary_of_w

WARRANT LIABILITY - Summary of warrant liability (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value Of Warrant Liability [Roll Forward]	'	'
Warrant liability (beginning balance)	$5,618,819	$111,636
Additional liability due to new grants	'	5,078,052
Loss(gain) on changes in fair market value of warrant liability	-4,556,678	429,131
Net warrant liability	$1,062,141	$5,618,819

WARRANT_LIABILITY_Detail_Textu

WARRANT LIABILITY (Detail Textuals) (USD $)	12 Months Ended		1 Months Ended				1 Months Ended		1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 17, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jul. 31, 2011	Apr. 30, 2012	Apr. 30, 2012	Apr. 30, 2012
			Common Stock	Warrant	Warrant	Warrant	Warrants granted during July 2011	Warrants granted during July 2011	Warrants granted during April 2012	Warrants granted during April 2012
							Common Stock	Common Stock	Common Stock	Shareholder and Brother of Chief Executive Officer
										Common Stock
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'	'
Term of warrants expired from date of grant	'4 years	'	'	'	'	'	'	'	'	'
Company issues the additional shares of common stock period	'2 years	'	'	'	'	'	'	'	'	'
Method used for fair value of warrant granted	'Black Scholes pricing model	'	'	'	'	'	'	'	'	'
Number of stock sold (in shares)	'	'	150,129,655	'	'	'	35,461	'	1,000,000	100,000
Number of share stock called by warrants	'	'	'	'	'	'	35,461	'	1,808,511	200,000
Exercise price of warrants (in dollars per share)	'	'	'	48.27	30.07	30.07	2.5	0.5	0.5	0.5
Loss (gain) on changes in fair market value of warrant liability	$2,366,218	($429,131)	'	'	'	'	'	'	'	'

EQUITY_Fair_value_assumptions_

EQUITY - Fair value assumptions (Details 1) (Common Stock Warrants)	3 Months Ended	1 Months Ended
	Mar. 31, 2008	Jul. 28, 2011
	Former board members	Consultants
Class of Warrant or Right [Line Items]	'	'
Risk-free interest rate at grant date	4.75%	0.39%
Expected stock price volatility	155.00%	172.10%
Expected dividend payout	'	'
Expected option in life-years	'5 years	'4 years

EQUITY_Transactions_involving_

EQUITY - Transactions involving warrants (Details 2) (Warrant)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Warrant	'	'
Class Of Warrant Or Right Outstanding [Roll Forward]	'	'
Number of Warrants, Outstanding	29,035	29,035
Number of Warrants, Granted	'	'
Number of Warrants, Exercised	-35	'
Number of Warrants, Canceled or expired	'	'
Number of Warrants, Outstanding	29,000	29,035
Class Of Warrant Or Right Weighted Average Price [Roll Forward]	'	'
Weighted average price per share, warrants outstanding	30.07	30.07
Weighted-Average Price Per Share, Granted	'	'
Weighted-Average Price Per Share, Exercised	28	'
Weighted-Average Price Per Share, Canceled or expired	'	'
Weighted average price per share, warrants outstanding	48.27	30.07

EQUITY_Warrants_Outstanding_De

EQUITY - Warrants Outstanding (Details 3) (Warrant)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Warrants Outstanding	'	'	'
Exercise price of warrants (in dollars per share)	48.27	30.07	30.07
Warrants Outstanding, Number Outstanding	29,000	29,035	29,035
Warrants Outstanding, Weighted Average Remaining Contractual Life	'2 years 5 months 5 days	'	'
Exercise Price $ 25	'	'	'
Warrants Outstanding	'	'	'
Exercise price of warrants (in dollars per share)	25	'	'
Warrants Outstanding, Number Outstanding	2,000	'	'
Warrants Outstanding, Weighted Average Remaining Contractual Life	'1 year	'	'
Exercise Price $ 50	'	'	'
Warrants Outstanding	'	'	'
Exercise price of warrants (in dollars per share)	50	'	'
Warrants Outstanding, Number Outstanding	27,000	'	'
Warrants Outstanding, Weighted Average Remaining Contractual Life	'2 years 3 months	'	'

EQUITY_Detail_Textuals

EQUITY (Detail Textuals)	0 Months Ended			0 Months Ended
	Oct. 08, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 19, 2013	Oct. 08, 2012
				Common Stock [Member]	Common Stock [Member]
Reverse split of common stock	'5,000-to-1	'	'	'	'
Common stock, shares authorized	'	500,000,000	500,000,000	100,000,000	75,000,000,000
Increase Decrease In Common Stock Shares Authorized	'	'	'	500,000,000	100,000,000

EQUITY_Detail_Textuals_1

EQUITY (Detail Textuals 1) (USD $)

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Dec. 31, 2012

Jul. 16, 2012

Mar. 01, 2012

1-May-13

Jan. 17, 2013

Sep. 20, 2012

Apr. 23, 2012

Dec. 17, 2013

Nov. 14, 2012

15-May-12

Dec. 20, 2013

Sep. 23, 2013

Aug. 27, 2013

Apr. 15, 2013

Aug. 24, 2012

Jul. 18, 2012

Jun. 26, 2012

Apr. 18, 2012

Consultants

Consultants

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Schedule Of Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for consultants (in shares)

'

24,000

10,714

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Market value of shares issued to consultants

'

$60,000

$42,859

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of stock sold (in shares)

'

'

'

11,872,281

400,000

100,000

7,980,133

2,000,000

100,000

60,000

15,000,000

21,429

42,743

2,000,000

500,000

100,000

200,000

1,000,000

Aggregate purchase price of common stock sold

$100,000

'

'

'

$200,000

$50,000

'

$40,000

'

$300,000

$300,000

$15,000

$29,920

$400,000

$250,000

'

$100,000

$500,000

Number of share stock called by warrants

'

'

'

'

'

'

'

'

'

60,000

'

'

'

'

'

'

200,000

1,000,000

Exercise price of warrants (in dollars per share)

'

'

'

'

'

'

'

'

'

0.5

'

'

'

'

'

'

0.5

0.5

Term of warrants

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

'

'4 years

'4 years

EQUITY_Detail_Textuals_2

EQUITY (Detail Textuals 2) (USD $)

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Dec. 31, 2012

Dec. 31, 2013

Apr. 10, 2012

Apr. 23, 2012

Dec. 17, 2013

1-May-13

Jan. 17, 2013

Sep. 20, 2012

Apr. 23, 2012

Apr. 23, 2012

Apr. 23, 2012

Apr. 12, 2012

Series B Preferred Stock

Series B Preferred Stock

Common Stock

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Lyle Hauser

Mr. Kevin Hauser

Series B Preferred Stock

Lyle Hauser

Schedule Of Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock designated as Series B Convertible Preferred Stock

10,000,000

10,000,000

100,000

'

'

'

'

'

'

'

'

'

Liquidation preference stated value

'

'

$1

'

'

'

'

'

'

'

'

'

Number of votes entitled to be cast

'

'

0.00%

'

'

'

'

'

'

'

'

'

Total percentage of number of votes entitled to be cast per share

'

'

51.00%

'

'

'

'

'

'

'

'

'

Common stock for each share of Series B Preferred Stock

'

'

2

'

'

'

'

'

'

'

'

'

Shares issued, value

$100,000

'

'

'

'

'

$200,000

$50,000

'

$539

$96

$100,000

Number of stock sold (in shares)

'

'

'

'

150,129,655

11,872,281

400,000

100,000

7,980,133

5,383,594

964,539

100,000

Common stock issued for compensation

'

'

'

'

'

'

'

'

'

'

1,632,000

'

Warrants issued to purchase common stock to the investor

'

'

'

'

'

'

'

'

'

'

'

200,000

Warrants Outstanding, Exercise Price

'

'

'

'

'

'

'

'

'

'

'

0.5

Term of warrants

'

'

'

'

'

'

'

'

'

'

'

'4 years

Value of shares issued for compensation

'

'

'

'

'

'

'

'

'

'

$9,792,000

'

Number of preferred stock converted

'

'

'

100,000

'

'

'

'

'

'

'

'

Shares issued upon conversion of preferred stock

'

'

'

200,000

'

'

'

'

'

'

'

'

EQUITY_Detail_Textuals_3

EQUITY (Detail Textuals 3) (2006 Incentive Stock Plan)	1 Months Ended
	Jan. 31, 2006
2006 Incentive Stock Plan	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of shares of common stock reserved for issuance	2,000
Number of options granted to employees	1,128

EQUITY_Detail_Textuals_4

EQUITY (Detail Textuals 4) (Warrant)	12 Months Ended			3 Months Ended	1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Mar. 31, 2008	Jul. 28, 2011	Jun. 22, 2011
				Former board members	Consultants	Consultants
Class of Warrant or Right [Line Items]	'	'	'	'	'	'
Number of warrants awarded	'	'	'	35	27,000	2,000
Warrants Outstanding, Exercise Price	48.27	30.07	30.07	2,800	25	50
Term of warrants	'	'	'	'5 years	'3 years	'4 years
Method used for fair value of the warrants	'	'	'	'Black-Scholes pricing model	'Black-Scholes pricing model	'Black-Scholes pricing model

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details) (USD $)

12 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Dec. 31, 2012

Dec. 17, 2013

Nov. 04, 2013

Dec. 31, 2013

1-May-13

Jan. 17, 2013

Sep. 20, 2012

Apr. 23, 2012

Dec. 17, 2013

Nov. 14, 2012

15-May-12

Dec. 20, 2013

Sep. 23, 2013

Aug. 27, 2013

Apr. 15, 2013

Aug. 24, 2012

Jul. 18, 2012

Jun. 26, 2012

Apr. 18, 2012

Two 10% Secured Convertible Debentures [Member]

Two 10% Secured Convertible Debentures [Member]

Two 10% Secured Convertible Debentures [Member]

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Security Purchase Agreement

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Accredited Investors

Short-term Debt [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate purchase price of common stock sold

$100,000

'

'

'

'

$200,000

$50,000

'

$40,000

'

$300,000

$300,000

$15,000

$29,920

$400,000

$250,000

'

$100,000

$500,000

Number of stock sold (in shares)

'

'

'

'

11,872,281

400,000

100,000

7,980,133

2,000,000

100,000

60,000

15,000,000

21,429

42,743

2,000,000

500,000

100,000

200,000

1,000,000

Terms of conversion feature

'

'one year

'one year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Issuance Amount

'

'

'

$110,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'